Previous Close | 14.05 |
Open | 13.98 |
Bid | 0.00 x 2200 |
Ask | 0.00 x 3200 |
Day's Range | 13.70 - 14.14 |
52 Week Range | 7.09 - 14.47 |
Volume | |
Avg. Volume | 9,279,165 |
Market Cap | 15.834B |
Beta (5Y Monthly) | 1.06 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Nov 27, 2017 |
1y Target Est | N/A |
Corcept reports a robust financial performance and advances in clinical trials, despite facing potential generic competition.
The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling by the patent-focused U.S. Court of Appeals for the Federal Circuit against the company, which in 2018 had sued Teva and Apotex in Delaware for patent infringement after they applied to make generic versions of Vanda's Hetlioz, a circadian-rhythm drug used to treat rare sleep disorders.
WASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling by the patent-focused U.S. Court of Appeals for the Federal Circuit against the company, which in 2018 had sued Teva and Apotex in Delaware for patent infringement after they applied to make generic versions of Vanda's Hetlioz, a circadian-rhythm drug used to treat rare sleep disorders.